Biopharmaceutical company Celgene has partnered with German biotech Immatics to develop three T cell receptor ( hp ) therapies for cancer . Celgene will pay $ 75 m cash to Immatics , followed by up to $ 505 m per therapy in downstream treatments . these therapies can reach targets inside a tumour cell , while CAR - T therapies can only reach targets on the surface of cancer cells . Gilead Sciences , hp and TCR2 Therapeutics are among the other companies working on TCR therapies . Meanwhile , Celgene is expected to be acquired by Bristol - Myers Squibb .
Biopharmaceutical company Celgene has partnered with German biotech Immatics to develop three T cell receptor (TCR) therapies for cancer. Celgene will pay $75m cash to Immatics, followed by up to $505m per therapy in downstream payments. TCR therapies can recognise targets inside a tumour cell, while CAR-T therapies can only reach targets on the surface of cancer cells. Gilead Sciences, Novartis and TCR2 Therapeutics are among the other companies working on TCR therapies. Meanwhile, Celgene is poised to be acquired by Bristol-Myers Squibb.